Cargando…

Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study

INTRODUCTION: The phase 2/3 PROTECT VIII main study demonstrated efficacy and safety of BAY 94–9027 (damoctocog alfa pegol; Jivi(®)), a B‐domain‐deleted recombinant factor VIII (FVIII), site‐specifically PEGylated to extend its half‐life. AIM: To report the final efficacy and safety data for BAY 94–...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reding, Mark T., Pabinger, Ingrid, Holme, Pal Andre, Poulsen, Lone, Negrier, Claude, Chalasani, Pavani, Maas Enriquez, Monika, Wang, Maria, Meijer, Karina, Mancuso, Maria Elisa, Lalezari, Shadan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290859/ https://www.ncbi.nlm.nih.gov/pubmed/33818853 http://dx.doi.org/10.1111/hae.14297

Ejemplares similares

BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results
por: Lalezari, Shadan, et al.
Publicado: (2019)

Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027
por: Reding, Mark T., et al.
Publicado: (2020)

Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY 94-9027 for Severe Haemophilia A: A Post Hoc Analysis
por: Lalezari, Shadan, et al.
Publicado: (2020)

PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A
por: Mancuso, Maria Elisa, et al.
Publicado: (2021)

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study
por: Reding, Mark T., et al.
Publicado: (2023)

PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A
por: Santagostino, Elena, et al.
Publicado: (2020)

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis
por: Mancuso, Maria Elisa, et al.
Publicado: (2021)

Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
por: Coyle, T E, et al.
Publicado: (2014)

Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison
por: Hakimi, Zalmai, et al.
Publicado: (2020)

Exploring the Impact of Infusion Frequency in Hemophilia A: Exit Interviews with Patients Participating in BAY 94-9027 Extension Studies (PROTECT VIII)
por: Wells, Jane R., et al.
Publicado: (2019)

Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach
por: Solms, Alexander, et al.
Publicado: (2019)

Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A
por: Batt, Katharine, et al.
Publicado: (2019)

Nonclinical Safety Assessment of a Long-Acting Recombinant PEGylated Factor Eight (BAY 94-9027) With a 60 kDa PEG
por: Ivens, Inge A., et al.
Publicado: (2019)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years
por: Mahlangu, Johnny, et al.
Publicado: (2020)

Factor VIII companion diagnostic for haemophilia
por: Hu, Chunxiao, et al.
Publicado: (2022)

Identification of a novel mutation in the factor VIII gene causing severe haemophilia A
por: Nissen, S. K., et al.
Publicado: (2018)

Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
por: Pocoski, Jennifer, et al.
Publicado: (2016)

Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non‐severe haemophilia A
por: Rejtő, Judit, et al.
Publicado: (2020)

Once‐weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8‐GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial)
por: Curry, Nicola, et al.
Publicado: (2019)

Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX
por: Rocino, Angiola, et al.
Publicado: (2017)

Impact of extreme weight loss on factor VIII concentrate pharmacokinetics in haemophilia
por: van Moort, Iris, et al.
Publicado: (2021)

Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection
por: Solms, Alexander, et al.
Publicado: (2020)

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study
por: Nolan, Beatrice, et al.
Publicado: (2020)

Biological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophilia
por: Turecek, Peter L., et al.
Publicado: (2020)

Proteomic analysis of ceftazidime and meropenem-exposed Pseudomonas aeruginosa ATCC 9027
por: Ngo, Hong Loan, et al.
Publicado: (2023)

Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A
por: Persson, Sofie, et al.
Publicado: (2022)

Ex vivo factor VIII‐modified proliferating human hepatocytes therapy for haemophilia A
por: Zhang, Kun, et al.
Publicado: (2023)

Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients
por: van Moort, Iris, et al.
Publicado: (2020)

Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature
por: Iorio, Alfonso, et al.
Publicado: (2022)

Surgical outcomes in patients with haemophilia A or B receiving extended half‐life recombinant factor VIII and IX Fc fusion proteins: Real‐world experience in the Nordic countries
por: Lehtinen, Anna‐Elina, et al.
Publicado: (2022)

Real-World Clinical Outcomes and Replacement Factor VIII Consumption in Patients with Haemophilia A in Italy: A Comparison between Prophylaxis Pre and Post Octocog Alfa (BAY 81-8973)
por: Cortesi, Paolo Angelo, et al.
Publicado: (2022)

Haemophilia in France: Modelisation of the Clinical Pathway for Patients
por: Beny, Karen, et al.
Publicado: (2022)

Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)
por: Kavakli, K, et al.
Publicado: (2015)

Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A
por: Du, Lily M., et al.
Publicado: (2013)

Clinical Application of Factor VIII:C to VWF:Ag Ratio for the Screening of Haemophilia A Carriers
por: Yoo, Ki-Young, et al.
Publicado: (2022)

Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians
por: Borchiellini, Alessandra, et al.
Publicado: (2021)

Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study
por: Kenet, Gili, et al.
Publicado: (2021)

Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS
por: Lalezari, S, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rlsl2tfoejq8pu2g5qqlb2cbsk